Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant platinum-doublet chemotherapy followed by vebreltinib in resected MET exon 14 skipping NSCLC
ChiCTR2400085552Phase 4Recruiting
- Sponsor
- First Affiliated Hospital, Zhejiang University School of Medicine
- Start
- Jun 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of vebreltinib in non-small cell lung cancer (NSCLC), sponsored by First Affiliated Hospital, Zhejiang University School of Medicine. Primary endpoint: 1-year disease-free rate. Started Jun 2024; status: recruiting.
02
Drugs
vebreltinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2400085552.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400085552.